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ABSTRACT 
Background: Leukocytes have previously been shown to express detectable levels of the protein 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). This study aims to evaluate the 
application of flow cytometry analysis to detect CFTR expression, and changes thereof, in these 
cells. 
Methods: Aliquots (200 µL) of peripheral whole blood from; 12 healthy control volunteers 
(CTRLs), 12 carriers of a CFTR mutation (CFC) and 40 cystic fibrosis (CF) patients carrying 
various combinations of CFTR mutations, were incubated with specific fluorescent probes 
recognizing CFTR protein expressed on the plasma membrane of leukocytes. Flow cytometry was 
applied to analyze CFTR expression in monocytes, lymphocytes and in polymorphonuclear (PMN) 
cells. 
Results: CFTR protein was detected in monocytes and lymphocytes whereas inconclusive results 
were obtained from analysis of PMN cells. MFI ratio value and %CFTR positive cells above a 
selected threshold were the two parameters selected to quantify CFTR expression in cells. Lowest 
variability and the highest reproducibility were obtained when analysing monocytes. ANOVA 
results indicated that both parameters were able to discriminate monocytes of healthy controls and 
CF individuals according to CFTR mutation classes with high accuracy. Significantly increased 
MFI ratio values were recorded in CFTR-defective cells that were able to improve also CFTR 
function after ex vivo treatment with PTC124 (Ataluren), an investigative drug designed to permit 
the ribosome to read-trough nonsense CFTR mutations. 
Conclusions: The method described is minimally invasive and may be used in the monitoring of 
responses to drugs whose efficacy can depend on increased CFTR protein expression levels.  
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Cystic Fibrosis 
Leukocytes 
cystic fibrosis transmembrane conductance regulator  (CFTR) 
Genetic disease
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INTRODUCTION 
Cystic fibrosis (CF) is the most common recessively inherited disease among caucasians [1]. 
The affected gene encodes the protein Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR), which functions as an anion channel in epithelial cells. Since its discovery in 1989, 
biomedical research has focused on targeting the underlying genetic defect to identify a disease-
modifying therapy for CF patients. Over 1,900 mutations identified in the CFTR gene have been 
clustered in 5 major classes (available at http://www.genet.sickkids.on.ca/cftr/). Class I mutations 
impair CFTR protein synthesis, no CFTR protein reaches the plasma membrane and chloride 
transport through CFTR does not occur. Class II mutations cause subcellular mislocalization and 
rapid degradation of CFTR. The little CFTR protein that reaches plasma membrane often does not 
function properly. In class III and IV mutations CFTR is expressed on the plasma membrane but the 
chloride transport is impaired. Class V mutations have both reduced CFTR synthesis and a reduced 
number of CFTR channels that transport chloride through the plasma membrane appropriately [2]. 
A dysfunction of CFTR anion channel in epithelial cells is thought to be the main cause for 
hyperviscous mucus production, infections and inflammation in CF patients’ lungs. However, 
excessive neutrophil accumulation in the lung is also a hallmark of CF disease and altered leukocyte 
functions have also been hypothesized to significantly contribute to the pathogenesis of the disease. 
Several data support this vision. Already back in 1991 Yoshimura et al. [3] demonstrated mRNA 
encoding for CFTR in human leukocytes, but not until recently CFTR protein was detected in 
neutrophils [4,5], in lymphocytes [6,7] and in monocytes [8,9], in which it was shown to be 
involved in membrane potential regulation [8]. Monocytes can differentiate into macrophages and 
possible roles of CFTR in those cells include involvement in inflammation [10] and in bactericidal 
activities [11,12]. 
Class I mutations represent approximately 10% of total CFTR mutations associated with CF disease 
in patients worldwide [13]. In CF patients with this class of mutations the presence of a premature 
stop codon causes the translation of mRNA to cease prematurely. The resulting truncated CFTR 
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protein does not reach the cell membrane causing a severe impairment of chloride transport in 
epithelial cells. When exposed to corrector drugs, designed to overcome the defective codon 
readthrough by ribosomes, increased CFTR protein synthesis can be expected in cells. To test the 
efficacy of those drugs, variations of CFTR expression levels in easily accessible cells like 
peripheral blood leukocytes would be valuable. Semi-quantitative information on CFTR expression 
levels, as well as data of the molecular mass of detected proteins, can be obtained by western blot 
(WB). Nevertheless, this technique has limited utility in a monitoring program of CF patients due to 
complex processing of the sample and the relatively great amounts of biological material necessary 
to perform the analysis. On the contrary, flow cytometry (FC) analysis of cells performed on a few 
hundred microliters of peripheral blood may represent a very sensitive technique useful to quantify 
the relative number of CFTR molecules expressed in representative cells as well as their variations. 
The aim of this study is to evaluate the potential use of FC analysis in detecting the presence and in 
measuring relative CFTR protein levels in leukocytes. To our knowledge, only one study has 
recently  analyzed the expression of CFTR in peripheral blood leukocytes by flow cytometry [9]. 
However, lymphocytes were not studied and CFTR expression was investigated only in a few 
individuals. In order to test a setting closer to clinical applications we first evaluated the presence of 
CFTR in peripheral blood mononuclear cells (PBMCs). We then optimized two FC parameters for 
the comparison of CFTR expression levels in major leukocyte sub-populations in peripheral blood 
samples from groups of at least five CF patients representing the most frequent CFTR mutation 
classes. Moreover, we tested the sensitivity of FC parameters by analysing variations of CFTR 
expression levels induced by exposing monocytes from CF patients with nonsense mutation 
genotype to PTC124 (Ataluren), a drug able to promote the expression of CFTR in a CF mouse 
model with a CFTR-G542X nonsense mutation [14] and that is under clinical evaluation in a phase 
III study. The results of FC analysis were related to those of a CFTR functional assay performed in 
parallel on replicate samples from the same CF patients. 
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MATERIALS AND METHODS  
Patients 
Forty CF patients were grouped according to the class of CFTR mutations [2]. The control 
group (CTRL) consisted of 12 individuals selected among healthy volunteers. Additional control 
subjects included 12 healthy CF carriers (CFC), i.e. patients’ parents, with one mutated CFTR 
allele. Details about CFC and CF patients are shown in Table 1. Samples and data were used for 
analysis only after informed consent was obtained according to guidelines approved by the local 
Ethical Committee. 
 
Detection of biotinylated CFTR in peripheral blood mononuclear cells (PBMCs) 
Roughly 4x10
7
 PBMCs recovered from 25 mL buffy-coat samples were obtained by 
centrifugation on Ficoll gradient (GE Healthcare, Piscataway, USA). Cells were washed and then 
incubated for 30 minutes at +4°C with 2mM EZ-link® sulfo-NHS-biotin (Pierce Biotechnology, 
Rockford, U.S.A.). Excess biotin was removed by three washes with PBS containing 100mM 
glycine. Total cell proteins were extracted as described previously [8]. A quantity of 65 µg total 
proteins was immunoprecipitated using protein G sepharose (GE Healthcare, Piscataway, USA) and 
either of two different rabbit anti-CFTR antibodies (Alomone Labs, Jerusalem, Israel and Santa 
Cruz Biotechnology, Dallas, U.S.A.) recognizing the C- and N-terminus of CFTR, respectively. 
Either of two other different rabbit antibodies were utilized to control both efficiency and specificity 
of the immunoprecipitation procedure. Immunoprecipitates were denatured for 20 minutes at 40°C 
in Laemmli sample buffer, separated on a 6% acrylamide/bisacrylamide gel and transferred onto 
nitrocellulose membrane (GE Healthcare, Piscataway, U.S.A.). Membranes were washed, blocked 
and then incubated with 40 ng/mL HRP-conjugated streptavidin (Jackson Immunoresearch 
Laboratories, West Grove, U.S.A.), which binds to biotinylated proteins. Signal was detected on 
nitrocellulose membrane by the HRP-catalyzed ECL method (Millipore, Billerica, U.S.A.). 
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Immunofluorescence labelling of leukocytes 
Aliquots of 100 µL peripheral blood were used for FC analysis within five hours after blood 
withdrawal. Red blood cells were lysed in 1 mL solution containing: 0.89% (w/v) NH4Cl, 0.10% 
(w/v) KHCO3 and 200µM EDTA. After addition of 5% FBS in PBS, samples were centrifuged for 
7 min at 300xg at room temperature, the supernatant was reduced to a volume of 100 µL and 10 µL 
human serum (Sigma-Aldrich, Missouri, U.S.A.) was added. Cells were incubated with a mouse 
anti-CD14 antibody conjugated with the tandem fluorophores PE-Cy7(λnm = 488ex/>750em) or with 
allophycocyanin (APC) fluorochrome (λnm = 635ex/670em) according to manufacturer (BioLegend, 
San Diego, U.S.A. and Miltenyi Biotech, Germany, respectively). Washed cells were fixed for 20 
minutes at room temperature in 0.5 mL Fixation buffer (BioLegend, San Diego, U.S.A.). After 
treatment with Permeabilization Wash Buffer (PWB) according to manufacturer (BioLegend, San 
Diego, U.S.A.), cells were incubated (45 min at room temperature) with primary antibody 
(polyclonal rabbit anti-CFTR Alomone Labs, Jerusalem, Israel, 800 ng or 150 ng/100 µL blood 
sample from lot numbers 04 and 05, respectively). To decrease non specific binding, human serum 
(10% v/v) was added to sample before its incubation with primary antibody. To measure the 
contribution of non specific antibody-cell interactions the rabbit polyclonal primary antibody was 
pre-incubated with a blocking peptide (4 µg) corresponding to aminoacids 1468-1480 in the C-
terminal domain of CFTR. A mouse monoclonal anti-CFTR antibody, clone 13-1 (1.2 µg/sample) 
from R&D System, Minneapolis, U.S.A., was used in some replicate samples. This monoclonal 
antibody recognizes an epitope on the R-domain of CFTR. Goat anti-Rabbit IgG antibody (1.5 
µg/sample) conjugated with Alexa Fluor (AF) 488 (Life Technologies, Carlsbad, U.S.A.) or Rabbit 
F(ab’)2 anti-Mouse Ig antibody (300 ng/sample) conjugated with FITC (DAKO, Glostrup, 
Denmark) were used as secondary antibodies. 
 
Flow cytometric (FC) analysis of CFTR expression in leukocytes and effect of PTC124 
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Fluorescence, forward and side scatters were determined in cells using a MACSQuant Analyser 
(Miltenyi Biotech, Cologne, Germany) processing 80000 total events and performing statistics of 
roughly 2000 monocytes with FCS Express v3 software (De Novo Software, Los Angeles, U.S.A.). 
Granulocyte, lymphocyte and CD14 positive monocyte cell populations were identified and gated 
by visual inspection of dot plots using side scatter values versus CD14/PE-Cy7 fluorescence values. 
A threshold value (background) was determined in sample stained with rabbit polyclonal anti-CFTR 
antibodies pre-incubated with blocking peptide. The percentage of events above the threshold 
corresponded to background noise. The percentage of CFTR positive cells (%CFTR positive cells) 
was calculated as the difference between the percentage above the threshold obtained without 
blocking peptide and background noise. The ratio between Mean Fluorescence Intensity (MFI) 
values in samples processed with and without blocking peptide was related to CFTR expression 
levels in cells. Average MFI ratio values and average %CFTR positive cells values were used to 
compare different groups of individuals. 
Flow cytometric analysis of CFTR expression levels was performed using also enriched 
monocytes (>70% purity) from 6 CF patients carrying a CFTR nonsense mutation. Results obtained 
from monocytes exposed ex vivo for 24 hours to 10µM PTC124 (Selleckchem, Houston, U.S.A.) 
were compared to untreated controls (CTRL). This small-molecular agent has been designed by 
PTC Therapeutics to make ribosomes less sensitive to premature stop codons. Fixed cells were 
stained using the polyclonal rabbit anti-CFTR antibody, as described above. A total of 10.000 
events corresponding to purified cells were registered and analysed for CFTR expression levels. 
 
Functional CFTR assay 
CFTR function was tested by imaging cell membrane potential of adherent monocytes using 
the probe bis-(1,3-diethylthiobarbituric acid) trimethine oxonol (DiSBAC2(3), Life Technologies, 
Carlsbad, U.S.A.), as previously described [8]. In this assay, CFTR function is expressed by a CF 
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index, which has positive values when CFTR anion channel functions properly and negative values 
when its ability to transport chloride anions through plasma membrane is reduced or absent. 
 
Sub-cellular localization and quantification of CFTR by confocal microscopy 
To localize the cellular distribution of fluorescent probes corresponding to CFTR and CD14 
molecules, leukocytes already labelled with antibodies as described above were stained also with 
3µM DAPI (Sigma-Aldrich, Missouri, U.S.A.). Cells were plated onto microscopy slides, dried and 
cover slip was added with anti-fading mounting medium. They were then analysed with a Leica 
TCS-SP5 confocal microscope (Leica Microsystem, Wetzlar, Germany). Wavelengths were the 
same as those selected in flow cytometric studies whereas for DAPI the following wavelengths 
were used: λnm = 360ex/460em. Z-stack images were merged to quantify CFTR signal in cells. Gray 
scales of 32-bit TIFF images were measured with ImageJ ver 1.43u. Around 10 cells/sample were 
analysed and background values were subtracted. Mean values of cells from each CF patient and 
each healthy CTRL donor were used to compare the two groups. 
 
Statistics 
SigmaStat software version 3.0 (SPSS Inc., Chicago, U.S.A.) was used for statistical 
calculations. According to the distribution of results, parametric and/or nonparametric statistics 
were applied to test hypotheses on the means and/or the medians. The α value was set to 0.05 and 
the level of significant difference to P < 0.05. 
 
RESULTS 
 
Cell membrane localization of CFTR in peripheral blood mononuclear cells 
CFTR expression in non CFTR-defective PBMCs is illustrated in Figure 1. Two different forms 
of biotinylated CFTR (lanes 2 and 4) were immunoprecipitated (IP) by either of two rabbit anti-
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CFTR antibodies recognizing the C-terminus or N-terminus of CFTR. The two antibodies may have 
different IP efficiency, as suggested by the different signal intensities of common bands detected at 
around 150 and 180 kDa. The specificity of the result is suggested by the absence of bands in the 
same sample immunoprecipitated with either of two non CFTR-related rabbit polyclonal antibodies 
(Figure 1, lanes 1 and 3). Figure 2 shows the different expression of CFTR in leukocytes from 
healthy CTRLs (A-D) and from two CF patients with genotypes R1158X/E585X (E-G), and 
W1282X/F508del (H). Leukocytes were stained with rabbit polyclonal anti-CFTR antibody 
(Figures 2D and H) or with mouse monoclonal anti-CFTR antibody (Figures 2B and F) and anti-
CD14 antibody (Figures 2A and E). A partial co-localization of CFTR and CD14 on monocyte 
plasma membrane is shown in Figure 2C.  A more intense green fluorescence, corresponding to 
CFTR staining, was observed in monocytes from healthy CTRLs (Figures 2B and D) than in 
monocytes from CF patients (Figures 2F and H) whereas the red fluorescence intensity of CD14 
staining is similar in monocytes of CTRLs and CF patients. This was observed in results obtained 
by the polyclonal as well as by the monoclonal antibodies. Histogram in Figure 2 summarize the  
quantification data of CFTR signal in cells from three healthy CTRL donors and from three CF 
patients. A paired t-test revealed a significant difference between the mean values of the two groups 
(P=0.018).  
 
Setting parameters for FC analysis of whole blood samples: MFI ratio and percent of CFTR 
positive cells 
Figure 3 illustrates how sub-cellular populations of CFTR positive leukocytes were identified 
by FC analysis in two whole peripheral blood samples stained with anti-CD14 and with polyclonal 
rabbit anti-CFTR antibodies. A sub-population of CD14 positive cells, different from lymphocytes 
and granulocytes that stained very weakly with anti-CD14 antibody, can be easily distinguished 
plotting side scatter versus PE-Cy7 fluorescence intensity values (Figure 3A). This highly CD14 
positive sub-population with relatively low side scatter values was assigned to monocytes. Figures 
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3B and D illustrate the positioning of thresholds for CFTR positivity in monocytes from a healthy 
CTRL (Figure 3B) and from a CF patient (Figure 3D) homozygous for a class I CFTR mutation 
(R1162X). In the presence of blocking peptide (Figures 3B and D) less than 10% CTRL and CF 
monocytes incubated with rabbit polyclonal anti-CFTR antibody had AF488 fluorescence detected 
above the threshold. Without blocking peptide (Figures 3C and E) those percentages increased to 
about 80% in monocytes from healthy CTRL (Figure 3C) and only to about 40% in monocytes 
from CF patient (Figure 3E). Thresholds positioned in the same way were utilized to distinguish 
CFTR expression from the background noise in lymphocytes. The ratio between MFI value of the 
replicate sample processed without blocking peptide and the MFI value of the corresponding 
replicate sample processed with blocking peptide reflected CFTR expression in sub-populations of 
leukocytes being analysed. 
 
Reproducibility and robustness of FC analysis 
The same operator labelled and analyzed different blood withdrawals from the same subject to 
test the repeatability of the FC analysis. Table 2 summarizes the different test conditions and 
results. Intraindividual biological and technical (eg. different batches of reagents) variabilities were 
tested by separately analysing blood withdrawals, obtained within a period of two years, from two 
subjects. Samples from one of these subjects (number 2, Table 2) were also analysed frequently 
during this period, and results obtained with either of two different anti- CFTR antibody batches 
(lots 04 and 05) are presented in order to highlight the contribution of this parameter to the overall 
variability. The within-day repeatability was tested twice (Day A and Day B, Table 2) by 
performing the labelling and analysis in parallel of four replicates using the same blood sample and 
the same reagents. The analytical variability decreased significantly when testing the within-day 
repeatability, as shown by the coefficient of variation (CV) of MFI ratio values (Table 2) resulting 
1.6% and 2.8% in the two tests performed, respectively. 
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To test the reproducibility of the FC test, blood samples from the same subject were labelled 
and analyzed repeatedly (n=6) during a period of ten months by two operators not working in 
parallel. Operator 1, who performed the tests of repeatability above, obtained the following results; 
(MFI ratio: mean = 1.88, CV = 11.0% and %CFTR positive monocytes: mean = 84.2, CV = 5.8%) 
Operator 2, who performed this FC analysis less frequently, obtained the following results; (MFI 
ratio: mean = 2.11, CV = 17.3% and %CFTR positive monocytes: mean = 82.0, CV = 12.6%). 
To test how robust the FC analysis was, a comparison was performed on mean values 
(mean±SD) of MFI ratio and of %CFTR positive monocytes in blood samples from healthy CTRLs, 
from CFC healthy individuals and from CF patients. Patients were grouped according to their 
membership in four different CFTR mutation classes: I+I (n = 12), I+II (n = 12), II+II (n = 11), and 
I+V (n = 5). ANOVA analysis was followed with Holm-Sidak method and the results, summarized 
in Figure 4, show that monocytes of all CF patient groups had significantly lower average MFI 
ratio values than monocytes of healthy CTRLs. Average MFI ratio value was significantly lower in 
monocytes of CF patients with class I mutations on both alleles (Figure 4 A, I+I)  than in 
monocytes of healthy CFC individuals, but no significant difference was observed among groups of 
CF patients or between healthy CTRLs and healthy CFC individuals. It may be noted that 
interindividual variability, as indicated by CV%, was comparable among groups and also 
comparable to the intraindividual variability shown in Table 2. On the contrary, greater variability 
was observed among values indicating %CFTR positive monocytes in some groups, as shown in 
Figure 4 B. Nevertheless, the results of Holm-Sidak method indicated that mean values of %CFTR 
positive monocytes were significantly different in the group of healthy CTRLs, or in the group of 
CFC individuals, and groups of CF patients, but differences were also observed among some CF 
groups as indicated in Figure 4 B.  
MFI ratio values reflecting CFTR expression in lymphocytes were not normally distributed and 
significant differences identified among groups by Kruskall-Wallis ANOVA on ranks (P = 0.003) 
were not further indicated by multiple pair-wise comparisons performed with Dunn’s method.  The 
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%CFTR positive lymphocyte mean values resulted significantly different among groups (ANOVA 
P<0.03). In this case, pairs-wise comparison by Holm-Sidak method identified differences between; 
healthy CTRLs (38.9±13.3) and class I+II CF patients (16.0±12.8, P = 0.004), CFC individuals 
(26.7±19.2) and class II+II CF patients (45.4±21.9). Class I+II CF patients with the lowest average 
%CFTR positive lymphocyte values resulted significantly different also from classes II+II 
(P<0.001), I+I (32.2±19.1, P = 0.004) and I+V (42.8±17.8, P = 0.004) CF patients. 
However, the high CV% values ranging from 34% in CTRLs to 80% in the class I+II group 
reflect an important contribution of interindividual variability when %CFTR positive lymphocytes 
were compared. 
 
Detection of drug-induced CFTR expression variations in monocytes by FC analysis 
Type I mutations are expected to severely impair CFTR expression in CF patients. The CFTR 
corrector PTC124 (Ataluren) is currently under clinical evaluation for its potential to restore CFTR 
protein expression and function as chloride channel.  In order to properly associate the results of FC 
analysis to a genuine drug response, FC analysis and a CFTR functional assay were performed in 
replicate samples of monocytes from 6 CF patients with different CFTR genotypes (all including a 
CFTR nonsense mutation) by two researchers unaware of the other’s results. The results are 
summarized in Table 3. In monocytes from patients #1 and #2, exposed ex vivo for 24 hours to 
10µM PTC124, the MFI ratio values increased 25% and 12%, respectively, as compared to control 
samples (0.1% DMSO in cell culture medium). These variations are greater than those measured in 
within-day replicates (CV% <3%, see above and Table 2). Functional assay run in parallel showed 
a recovery of CFTR function in the same samples. In monocytes from the remaining four patients 
CFTR expression levels were unchanged (differences between treated and untreated samples were 
lower than 3%). Interestingly, we did not detect any improvement of CFTR function either in these 
same four samples exposed to PTC124. 
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DISCUSSION 
There is increasing evidence that myeloid cells may play an important role in the pathogenesis 
of CF [15]. Therefore, the measurement of CFTR expression in easily accessible peripheral blood 
leukocytes has important implications, not only as surrogate biomarker but also as a way to monitor 
the correction of the defect in cells that are key players in CF. This monitoring may be of particular 
importance because drugs targeting defective CFTR are already available and others are in 
advanced stages of clinical evaluations for the therapy of CF patients [16]. Different methods to 
evaluate the effects of CFTR corrector drugs in patients suffer from some objective limitations and 
the availability of a reproducible analytical method capable of detecting CFTR expression in human 
leukocytes might represents an important advance in this context.  
The localization of CFTR protein on the plasma membrane of peripheral blood leukocytes was 
verified by a cell surface protein biotinylation approach of intact cells. Combining 
immunoprecipitation, gel electrophoresis and streptavidin detection of biotinylated proteins we 
revealed a band at around 150 kDa that was thicker than that at around 180 kDa, which is the 
predicted molecular mass of fully glycosylated and mature form of the CFTR protein (Figure 1, 
lanes 2 and 4). This 150 kDa band may represent both the product of a partial degradation of the 
CFTR protein during or after the biotinylation process as well as a differentially processed form of 
CFTR, as indicated previously [8]. A role of calpain in the turnover of membrane bound CFTR has 
already been suggested in PBMCs [17]. However, relative masses described for calpain-derived 
CFTR fragments were 70 kDa and 100 kDa, respectively. Therefore the 150 kDa band should not 
represent the product of CFTR digestion by calpain. CFTR protein partially co-localizes with CD14 
antigen on the plasma membrane of monocytes as revealed by confocal microscopy studies. 
Therefore we set conditions to detect CFTR expression in peripheral blood leukocytes by flow 
cytometry. While we could detect fluorescence related to CFTR expressed in monocytes and 
lymphocytes, the possibility to detect a specific CFTR signal in granulocytes was precluded in our 
study, probably because the permeabilization of plasma membrane induced high levels of auto-
Page 15 of 37
John Wiley and Sons, Inc.
Cytometry, Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 16 
fluorescence in those cells (data not shown). Granulocytes, which represent the most abundant cell 
population in peripheral blood, have been reported to express CFTR [4,5]. However, altered CFTR 
protein expression levels in neutrophils have been related to inflammation [4]. Also absent CFTR 
expression as detected by FC in neutrophils has been reported [9], but low signal to noise ratio 
values might not have been properly considered and the contribution of high MFI values obtained 
with an isotype control antibody may have been underestimated. When we analysed CFTR 
expression in lymphocytes, the second largest sub-population of leukocytes in peripheral blood 
samples, we noticed low autofluorescence after cell permeabilization making lymphocytes more 
suitable than granulocytes for CFTR expression analysis by FC. Moreover, some significant 
differences could be observed comparing MFI ratio values and the percentages of CFTR positive 
lymphocytes among groups. Unfortunately, those results were strongly influenced by a high degree 
of variability, possibly related to different CFTR expression in lymphocyte sub-populations (e.g. B- 
and T-cells). Specific biomarkers can be used to separate cell sub-populations, but they both impact 
the costs of the test and increase the complexity of interpretation of the results. Therefore, we 
focused on the optimization of MFI ratio values and %CFTR positivity in monocytes that, in our 
hands, represented the most suitable leukocyte sub-population for FC analysis of CFTR expression 
in peripheral blood. 
Both analytical and biological variability contributes to the results of ANOVA performed to 
distinguish differences among groups of CF patients, healthy CFC and healthy CTRL individuals 
according to the levels of  CFTR expression in monocytes. In order to limit analytical variability we 
pre-incubated the primary antibody with a blocking peptide instead of using an isotype control 
antibody to calculate MFI ratio values. In this way we reduced the experimental variability, for 
instance caused by use of different antibody lots or by stability over time of fluorescent probes 
ensuring that significant differences identified by ANOVA preferentially reflected biological rather 
than analytical variability. The MFI ratio values of CFTR staining  in monocytes showed lower 
variability as compared to those indicating %CFTR positive monocytes, as  suggested by the values 
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of CV% (Figure 4). This may be partially explained by the adjustment of the threshold value that is 
necessarily set experimentally during the analytic phase of the assay. Small changes of this 
threshold (between 5 to 10% of gated events) negatively impact on the results of the statistical 
analysis when groups of samples from different individuals are considered.  
We further wanted to test the capability of FC analysis to detect changes of CFTR expression 
levels in monocytes exposed ex vivo to PTC124 (Ataluren), a CFTR corrector under evaluation in 
clinical trials. As compared to untreated controls, monocytes exposed to PTC124 showed variations 
greater than those of within-day repeatability in samples from patients #1 and #2, thus suggesting 
that FC analysis in monocytes can be a useful method to monitor variations of CFTR expression 
levels related to drug treatment. Monocytes from the same blood sample showed a significantly 
increased CFTR function after exposure to PTC124, thus proving that the response to the drug 
measured by FC was reflecting a true recovery of CFTR expression on the cell membrane. This 
result interpretation was further supported by the evidence that the variations of CFTR expression in 
monocytes from patients # 3-6 were similar to the within-day repeatability of controls (1-2%) and 
that the results of the functional CFTR assay performed on the same samples documented the 
inability of PCT124 to induce any significant improvement of CFTR activity in those four samples. 
It is still not clear whether the responses to protein translation correctors might be influenced by an 
individual capability of ensuring a proper drug mediated read-through of the mutation by the 
translation machinery. A possible explanation of the absence of PTC124 effects in four cases out of 
six may be an absence of substrate due to an increased degradation of mRNA containing a 
premature stop codon, as discussed by Linde and Kerem [18]. Being the patients heterozygous for a 
nonsense mutation, another possible influence might derive from the presence of the second 
mutation that might impact on the capability to respond to the treatment. Variability of responses to 
drugs in cells and patients are common occurrence and the observed concordance between 
expression and the functional assays allows us to conclude that FC analysis might represent a 
powerful approach for the evaluation of responses to drugs targeting specific basic defects in CF 
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leukocytes. However, we realize that the robustness of this analytical approach must be confirmed 
in a greater number of observations either ex vivo or in vivo before proposing its use in the follow-
up of CF patients. 
In conclusion, we have described a relatively simple method to test CFTR expression in 
leukocytes starting from a few milliliters of peripheral blood that can be easily obtained from 
patients without too much discomfort. Once validated, the test might represent a convenient 
approach for the monitoring of selected therapies in CF patients. 
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Figure legends 
 
Fig. 1. Detection of CFTR in peripheral blood mononuclear cells (PBMCs). After biotinylation of 
intact PBMCs, protein extracts were immunoprecipitated with either of two different rabbit anti- 
CFTR antibodies recognizing the C-terminus (lane 2) or the N-terminus (lane 4) of CFTR and 
compared with samples incubated with either of two different rabbit control antibodies (lanes 1 and 
3, respectively). Proteins separated on 6% acrylamide gel were transferred onto nitrocellulose 
membrane and biotinylated proteins were detected with HRP-conjugated streptavidin and ECL. In 
lanes 2 and 4, two bands detected at around 150 kDa and at 180 kDa were assigned to CFTR. 
 
Fig. 2. Confocal analysis of CFTR expression in leukocytes.  
Upper panel. Leukocytes from a healthy individual (A-C) and from a CF patient with genotype 
R1158X/E585X (E-G). A and E: cells  stained with APC-conjugated anti- CD14 antibody, fixed 
and then stained in B and C with a mouse monoclonal (clone 13-1) anti-CFTR and FITC-
conjugated secondary antibodies (B and F). Merged images are shown in C and G. The green 
fluorescence of a CFTR positive monocyte from a healthy CTRL individual is shown in B; a 
granulocyte and a CD14 positive monocyte are shown in E. Leukocytes from a healthy CTRL in D 
and from a CF patient (genotype W1282X/F508del) in H were stained with a polyclonal rabbit anti-
CFTR antibody and detected with an AF488-conjugated secondary antibody. Nuclei were stained 
with DAPI (blue) and shown in all images, except in B and in F. Scale bar = 10 µm. 
Lower panel:  Quantification of fluorescence signals in cells from healthy CTRL donors and from 
CF patients (two patients with I+I and one patient with I+II mutation classes). Bars are 
means±S.E.M., paired t-test, P=0.018, n=3. 
 
Fig. 3. Flow cytometry analysis of dot-plot graphs of human leukocytes in whole blood samples of 
healthy CTRLs. A. The separation of granulocytes, monocytes and lymphocytes sub-populations by 
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plotting side scatter vs. fluorescence emitted by PE-Cy7 fluorochromes (CD14, monocytes). 
Forward scatter values of gated monocytes from a healthy CTRL (B and C) and a CF patient with 
genotype R1162X/R1162X (D and E) plotted vs CFTR protein signal detected in green channel by 
AF488 fluorochrome. The threshold of CFTR-signal (red line) was set to obtain 90-98% total 
monocytes, stained with anti-CFTR antibody pre-incubated with blocking peptide , below the value 
(B and D). Cells stained with anti-CFTR antibody without blocking peptide are shown in C and E, 
respectively. To calculate the percentage of CFTR positive monocytes the values in B (or in D) 
were subtracted from values in C (or in E), respectively (eg. 83.4 – 5.0 = 78.4%). 
 
Fig. 4. FC analysis of CFTR expression data in monocytes. Box and whisker plots (25
th
-75
th
 
percentiles) of MFI ratio values (A) and percent CFTR positive monocyte values (B) in healthy 
controls (CTRLs), healthy CF carriers (CFC) and cystic fibrosis (CF) patients grouped according to 
CFTR mutation class (I, II and V) being carried. The midline in boxes indicates median and 
whiskers represent the lowest and highest values, respectively. Symbols indicate significant 
differences (* p<0.05, ** p<0.01 and *** p<0.001) identified by Holm-Sidak method used to 
compare means of pairwise groups. 
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Table 1. Subjects with known genotype enrolled in the study. 
# 
Mutation 
class 
Gender 
Age 
(years) 
G  e  n  o  t  y  p  e 
Healthy carriers of a CFTR mutation (CFC) 
1 I F 48 WT G542X 
2 I F 39 WT R1162X 
3 I M 47 WT R1162X 
4 I F 44 WT R1162X 
5 I F 62 WT 4013insT 
6 I F 61 WT R1162X 
7 I F 58 WT 1717-1G>A 
8 I M 52 WT 2183AA>G 
9 I F 56 WT R1162X 
10 I M 71 WT W1282X 
11 II F 38 WT F508del 
12 II F 46 WT F508del 
CF patients 
13 I + I M 17 G542X G542X 
14 I + I M 26 R1162X R1162X 
15 I + I M 33 R1162X R1162X 
16 I + I M 35 W1282X 621+1G>T 
17 I + I F 13 R1162X R1162X 
18 I + I  M 20 E585X R1158X 
19 I + I F 44 R1162X R1162X 
20 I + I F 25 G542X R553X 
21 I + I F 36 Q552X CFTRdele17a-18 
22 I + I M 37 G542X CFTRdele1 
23 I + I M 31 Q552X 2183AA>G 
24 I + I M 12 R1162X R1162X 
25 I + II M 18 Q39X F508del 
26 I + II F 20 G542X F508del 
27 I + II F 42 R1162X F508del 
28 I + II F 23 R1162X F508del 
29 I + II F 28 W57X F508del 
30 I + II M 28 Q552X F508del 
31 I + II M 14 R1162X F508del 
32 I + II F 25 W1282X F508del 
33 I + II M 11 G542X F508del 
34 I + II M 16 Q552X F508del 
35 I + II F 25 R1162X F508del 
36 I + II F 23 R1162X F508del 
37 I + V M 43 R1162X 3849+10kbC>T 
38 I + V F 32 R1162X 2789+5G>A 
39 I + V F 38 R1162X 3849+10kbC>T 
40 I + V M 46 G542X 3849+10kbC>T 
41 I + V F 24 R1162X 3849+10kbC>T 
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42 II + II M 40 F508del F508del 
43 II + II F 37 F508del F508del 
44 II + II F 21 F508del F508del 
45 II + II F 38 F508del F508del 
46 II + II M 17 F508del F508del 
47 II + II M 42 F508del F508del 
48 II + II F 22 F508del F508del 
49 II + II M 43 F508del F508del 
50 II + II F 42 F508del F508del 
51 II + II F 29 F508del F508del 
52 II + II M 13 F508del F508del 
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Table 2. 
 
  MFI ratio 
%CFTR positive 
monocytes 
 n Mean CV Mean CV 
Subject 1i (♀) 6 1.88 11.0% 84.2 5.8% 
Subject 2i (♂) 6 1.95 13.1% 83.7 13.9% 
Lot 04ii (♂) 21 2.13 21.7% 82.7 12.8% 
Lot 05ii (♂) 36 1.82 10.3% 74.8 14.6% 
Day Aiii (♂) 4 1.68 1.6% 62.8 10.5% 
Day Biii (♂) 4 1.64 2.8% 55.2 9.9% 
 
 
Table 2. Repeatability of FC analysis of CFTR expression in monocytes. i) The same operator 
repeated FC analysis six times of samples from the same control individuals in different days; ii) 
between-day repeatability was tested by analyzing different samples from the same individual with 
either antibody Lot 04 or Lot 05; iii) within-day repeatability was tested by analyzing one sample 
four times on the same day and using the same antibody Lot. 
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Table 3. 
 
ID # Gender Genotype 
MFI 
before 
PTC124 
MFI 
after 
PTC124 
Variation 
(%CTRL) 
CF index 
CTRL 
CF index 
after 
PTC124 
Variation 
(%) 
1 F 
R1162X/ 
3849+10kbC>T 
1.47 1.84 +25 -41 +16 +57 
2 M 
R553X/ 
D1152H 
2.17 2.44 +12 -74 -33 +41 
3 F 
R1162X/ 
N1303K 
2.78 2.79 +1 -36 -32 4 
4 M 
S466X/ 
R1070Q/ 
1717-1G>A 
1.76 1.72 -2 -2 -22 -20 
5 M 
G542X/ 
3849+10kbC>T 
1.67 1.65 -1 -70 -95 -25 
6 M 
Q552X/ 
2183AA>G 
2.24 2.28 +2 -25 -64 -39 
 
Table 3. MFI ratio values and CF index variations induced in monocytes exposed ex vivo for 24 
hours to 10 µM PTC124 CFTR corrector or to 0.1% (v/v) DMSO (CTRL). Mutations being targets 
for PTC124 are underlined. CFTR expression levels and CFTR function reflected by MFI ratio and 
CF index values, respectively, were obtained by two researchers processing replicate samples of 
monocytes in parallel and unaware of the other’s result. An increased CFTR function results in an 
increment of CF index value. 
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Table 1. Subjects with known genotype enrolled in the study. 
# 
Mutation 
class 
Gender 
Age 
(years) 
G  e  n  o  t  y  p  e 
Healthy carriers of a CFTR mutation (CFC) 
1 I F 48 WT G542X 
2 I F 39 WT R1162X 
3 I M 47 WT R1162X 
4 I F 44 WT R1162X 
5 I F 62 WT 4013insT 
6 I F 61 WT R1162X 
7 I F 58 WT 1717-1G>A 
8 I M 52 WT 2183AA>G 
9 I F 56 WT R1162X 
10 I M 71 WT W1282X 
11 II F 38 WT F508del 
12 II F 46 WT F508del 
CF patients 
13 I / I M 17 G542X G542X 
14 I / I M 26 R1162X R1162X 
15 I / I M 33 R1162X R1162X 
16 I / I M 35 W1282X 621+1G>T 
17 I / I F 13 R1162X R1162X 
18 I / I  M 20 E585X R1158X 
19 I / I F 44 R1162X R1162X 
20 I / I F 25 G542X R553X 
21 I / I F 36 Q552X CFTRdele17a-18 
22 I / I M 37 G542X CFTRdele1 
23 I / I M 31 Q552X 2183AA>G 
24 I / I M 12 R1162X R1162X 
25 I / II M 18 Q39X F508del 
26 I / II F 20 G542X F508del 
27 I / II F 42 R1162X F508del 
28 I / II F 23 R1162X F508del 
29 I / II F 28 W57X F508del 
30 I / II M 28 Q552X F508del 
31 I / II M 14 R1162X F508del 
32 I / II F 25 W1282X F508del 
33 I / II M 11 G542X F508del 
34 I / II M 16 Q552X F508del 
35 I / II F 25 R1162X F508del 
36 I / II F 23 R1162X F508del 
37 I / V M 43 R1162X 3849+10kbC>T 
38 I / V F 32 R1162X 2789+5G>A 
39 I / V F 38 R1162X 3849+10kbC>T 
40 I / V M 46 G542X 3849+10kbC>T 
41 I / V F 24 R1162X 3849+10kbC>T 
42 II / II M 40 F508del F508del 
43 II / II F 37 F508del F508del 
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44 II / II F 21 F508del F508del 
45 II / II F 38 F508del F508del 
46 II / II M 17 F508del F508del 
47 II / II M 42 F508del F508del 
48 II / II F 22 F508del F508del 
49 II / II M 43 F508del F508del 
50 II / II F 42 F508del F508del 
51 II / II F 29 F508del F508del 
52 II / II M 13 F508del F508del 
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Table 2. 
 
  MFI ratio 
%CFTR positive 
monocytes 
 n Mean CV Mean CV 
Subject 1i (♀) 6 1.88 11.0% 84.2 5.8% 
Subject 2i (♂) 6 1.95 13.1% 83.7 13.9% 
Lot 04ii (♂) 21 2.13 21.7% 82.7 12.8% 
Lot 05ii (♂) 36 1.82 10.3% 74.8 14.6% 
Day Aiii (♂) 4 1.68 1.6% 62.8 10.5% 
Day Biii (♂) 4 1.64 2.8% 55.2 9.9% 
 
 
Table 2. Reproducibility of FACS analysis of CFTR expression in monocytes. i) The same operator 
repeated 6 times FACS analysis on the same control individuals in different days; ii) within-days 
repeatability performed analyzing different samples from the same individual with either antibody 
Lots 04 or 05; iii) within-day repeatability performed analyzing one sample four times on the same 
day  and using the same Lot of antibody. 
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Table 3. 
 
ID # Gender Genotype 
MFI 
before 
PTC124 
MFI 
after 
PTC124 
Variation 
(%CTRL) 
CF index 
CTRL 
CF index 
after 
PTC124 
Variation 
(%) 
1 F 
R1162X/ 
3849+10kbC>T 
1.47 1.84 +25 -41 +16 +57 
2 M 
R553X/ 
D1152H 
2.17 2.44 +12 -74 -33 +41 
3 F 
R1162X/ 
N1303K 
2.78 2.79 +1 -36 -32 4 
4 M 
S466X/ 
R1070Q/ 
1717-1G>A 
1.76 1.72 -2 -2 -22 -20 
5 M 
G542X/ 
3849+10kbC>T 
1.67 1.65 -1 -70 -95 -25 
6 M 
Q552X/ 
2183AA>G 
2.24 2.28 +2 -25 -64 -39 
 
Table 3. MFI ratio values and CF index variations induced in monocytes exposed for 24 hours to 10 
µM PTC124 CFTR corrector or to 0.1% (v/v) DMSO (CTRL). Mutations being targets for PTC124 
are underlined. CFTR expression levels and CFTR function reflected by MFI ratio and CF index 
values and were obtained by two researchers processing replicate samples of monocytes in parallel 
and unaware of the other’s results, respectively. An increased CFTR function results in an 
increment of CF index value.  
 
Page 35 of 37
John Wiley and Sons, Inc.
Cytometry, Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Cytometry Part A 
Author Checklist: MIFlowCyt-Compliant Items 
 
Requirement Please Include Requested Information  
1.1. Purpose Test CFTR expression in human leukocytes and specificity of anti-
CFTR antibody 
1.2. Keywords CFTR human leukocytes flow cytometry 
1.3. Experiment variables Biological samples from different human individuals 
1.4. Organization name and address Department of Pathology and Diagnostics, University of Verona, 
Strada Le Grazie 8, 37134 Verona, Italy 
1.5. Primary contact name and email address Claudio Sorio, claudio.sorio@univr.it 
1.6. Date or time period of experiment 2011-2013 
1.7. Conclusions A specific signal of CFTR expression was observed in monocytes 
and lymphocytes, but not in granulocytes 
1.8. Quality control measures Instrument calibrations with beads were performed 
2.1.1.1. (2.1.2.1., 2.1.3.1.) Sample description Human samples with known CFTR genotypes 
2.1.1.2. Biological sample source description Peripheral whole blood 
2.1.1.3. Biological sample source organism 
description  
Homo sapiens 
2.1.2.2. Environmental sample location EDTA treated polystyrene test tubes 
2.3. Sample treatment description Erythrocyte lysis, CD14 labelling, 4%PFA fixation, 
permeabilization, CFTR labelling 
2.4. Fluorescence reagent(s) description  Anti-CD14 antibody with PE-Cy7 or APC, secondary antibodies 
with AF488 or FITC 
3.1. Instrument manufacturer Miltenyi Biotech 
3.2. Instrument model MACSQuant Analyzer 
3.3. Instrument configuration and settings  Normal and same detector voltages among samples, optical filters 
installed Nov 2010 
4.1. List-mode data files  *We recommend all authors to submit their data files to 
http://flowr pository.org and to make them available for the 
peer-review process. If you have done so, please let us know by 
inserting the following codes (replace the red text): 
 
1) The link for peer-review process: 
http://flowrepository.org/id/FR-FCM-ZZ85 
 
2) The repository identifier: 
http://flowrepository.org/id/FR-FCM-ZZ85 
 
4.2. Compensation description  Tested and found not to be necessary 
4.3. Data transformation details  FCS files analysed with FCS Express v3 software (De Novo 
Software, Los Angeles, U.S.A.). 
4.4.1. Gate description  Based on SSC values and CD14-signal 
4.4.2. Gate statistics  Geometrical means of MFI values were used 
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4.4.3. Gate boundaries  
Subjective:  
5-10% of gated events below threshold obtained with anti-CFTR 
antibody preincubated with blocking peptide. 
Notes 
Feel free to use more space than allocated. 
You can embed graphics/figures in this document, if needed. 
Please make sure to save the document in Microsoft Word version 2003 or older, before uploading to ScholarOne 
Manuscripts. When uploading this checklist to ScholarOne Manuscripts, please choose the “Supplementary 
Material for Review” category. 
Please note that if your paper is accepted, the checklist will be published as an Online Supporting Information. 
 
For any questions, please contact the Cytometry Part A editorial office at Cytometrya@wiley.com. 
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